Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: A retrospective study of 54 cases

Annals of Oncology

Volumn 12, Issue 4, 2001, Pages 451-455

  Colita, A ^a   Belhabri, A ^a   Chelghoum, Y ^a   Charrin, C ^a   Fiere, D ^a   Thomas, X ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Acute myeloid leukemia; Chemotherapy; M6 subtype; Prognostic factors

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTARABINE; HEMOGLOBIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL PROTOCOL; CONTROLLED STUDY; ERYTHROLEUKEMIA; FEMALE; FEVER; GERIATRIC PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; PANCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 0034998540     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011133115435     Document Type: Article

References (29)

1. Copelli M. Di una emopatia sistemizzata rapresentala da una iperplasia eritroblastica (eritromatosi). Pathologica 1912; 4: 460-5.
2. Di Guglielmo G. Richerche di ematologica. Folia Medica 1917; 3: 386-96.
3. Dameshek W. The Di Guglielmo syndrome. Blood 1958; 13: 192.
4. Dameshek W. The Di Guglielmo syndrome revisited. J Hematol 1969; 34: 567-72.
5. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukemias. Br J Haematol 1976; 33: 451-8.
6. Sakurai M, Sandherg AA. Chromosomes and causation of human cancer and leukemia. XIII. An evaluation of karyotypic findings in erythroleukemia. Cancer 1976; 37: 790-804.
7. Trent JM, Durie BGM, Davis JR et al. Cytogenetic and clinical assessment of six patients with erythroleukemia. Anti-Cancer Res 1983; 3: 111-6.
8. Cuneo A, Van Orshoven A, Michaux JL et al. Morphologic, immunologic and cytogenetic studies in erythroleukemia: Evidence for multilineage involvement and identification of two distinct cytogenetic-clinicopathological types. Br J Haematol 1990; 75: 346-54.
9. Olopade OI, Thangavelu M, Larson RA et al. Clinical, morphologic, and cytogenetic characteristics of 26 patients with erythroblastic leukemia. Blood 1992; 80: 2873-82.
10. Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-5.
11. ISCN (International System for Cytogenetic Nomenclature). Guidelines for cancer cytogenetics. In Mitelman F (ed): Supplement to an International System for Human Cytogenetic Nomenclature. Basel: Karger 1991; 1-53.
12. Nakamura H. Cytogenetic heterogeneity in erythroleukemia defined as M6 by the French American British (FAB) Cooperative Group criteria. Leukemia 1989; 3: 305-9.
13. Ellison RR, Holland JF, Weil M et al. Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507-23.
14. Preisler HD. Failure of remission induction during the treatment of acute leukemia. Med Pediatr Oncol 1990; 4: 275-6.
15. Sculy RE, Murk EJ, McNeely BU. Case records of the Massachusetts General Hospital. N Engl J Med 1983; 308: 1081-91.
16. Atkinson J, Hrisinko MA, Weil SC. Erythroleukemia: A review of 15 cases meeting 1985 FAB criteria and survey of the literature. Blood Rev 1993; 6: 204-14.
17. Mazzella FM, Kowul-Vern A, Shrit MA et al. Acute erythroleukemia: Evaluation of 48 cases with reference to classification, cell proliferation, cytogenetics, and prognosis. Am J Clin Pathol 1998; 110: 590-8.
18. Goldberg SL, Noel P, Klumpp TR et al. The erythroid leukemias: a comparative study of erythroleukemia (FAB M6) and Di Guglielmo disease. Am J Clin Oncol 1998; 21: 42-7.
19. Davey FR, Abraham N Jr, Brunetto VL et al. Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): A CALGB study. Am J Hematol 1995; 49: 29-38.
20. Roggli VL, Subach J, Saleem A. Prognostic factors and treatment effects on survival in erythroleukemia: A retrospective study of 134 cases. Cancer 1981; 1101-5.
21. Forni A, Morco L. Chromosome studies in a case of benzene-induced erythroleukaemia. Eur J Cancer 1969; 5: 459-63.
22. Rozman C, Woessner S, Saez-Serrania J. Acute erythromyelosis after benzene poisoning. Acta Haematol 1968; 40: 234-7.
23. Mantovani G, Del Giacco GS, Marongiu F et al. Acute erythroblastic leukemia as a terminating event in a very long survivor (27 years) with Hodgkin's disease. Haematologica 1982; 67: 411-7.
24. Kadam PR, Balsara BR, Zafaraullah KZ et al. Cytogenetic features of erythroleukemia (EL): A study of 11 cases. Cancer Genet Cytogenet 1990; 50: 89-96.
25. Torrabadella M, Vallespi T. Chromosome analysis as an aid in differential diagnosis of erythroleukemia (M6) and myelodysplasia. Cancer Genet Cytogenet 1990; 49: 139-40.
26. Tamura K, Preisler HD. Treatment of erythroleukemia with anthracycline antibiotics and cytosine arabinoside. Cancer 1983; 51: 1795-9.
27. Sondergaard-Petersen H. The Di Guglielmo syndrome: A study of 17 cases. Acta Medica Scand 1975; 198: 165-74.
28. Bloomfield CD. Daunorubicin-prednisone treatment of erythroleukemia. Ann Intern Med 1974; 81: 746-50.
29. Brundman J, Bukowski RM, Greenstreet R et al. Prognostic factors affecting remission, remission duration, and survival in adult acute nonlymphocytic leukemia. Cancer 1979; 44: 1062-5.